The aim of this study was to report and analyze the rate of wound complications in patients treated for ovarian cancer with or without adjuvant bevacizumab.
Department of Obstetrics and Gynecology, Hospital Tenon,Assistance Publique des Hôpitaux de Paris, CancerEst, University Pierre et Marie Curie Paris 6, France. martin.koskas@wanadoo.fr